Elucidation of molecular mechanisms underlying such opposing effects on type I IFN responses by OTUD3 and OTUD5 and the identification of key molecules linked to both OTUDs may open up a new avenue for the development of novel treatments in patients with immune disorders including IBD. This evidence concerns the gene OTUD3 and inflammatory bowel disease.